苦黄注射液与门冬氨酸钾镁治疗病毒性肝炎的系统评价

摘要

目的:系统评价苦黄注射液与门冬酸钾镁治疗病毒性肝炎的疗效及安全性.方法:计算机检索Cochrane图书馆、PubMed、EMBase、中国知网(CNKI)、维普(VIP)、中国生物医学文献数据库(CBM),纳入苦黄注射液与门冬酸钾镁比较治疗病毒性肝炎的随机对照试验(RCT),对纳入的RCT进行质量评价,用Rev Man 5.0软件对数据进行Meta分析.结果:共纳入8项RCT,合计1 242例患者.Meta分析结果显示,苦黄注射液治疗病毒性肝炎的总有效率明显优于门冬酸钾镁,2组比较差异有统计学意义[RR=1.34,95％CI(1.22,1.46),P＜0.000 01];2组不良反应发生率比较差异无统计学意义[RR=3.33,95％CI(0.16,69.75),P=0.44].结论:苦黄注射液治疗病毒性肝炎的疗效优于门冬酸钾镁,但因为纳入研究文献质量较低,尚需高质量、大样本的随机对照试验加以验证.%OBJECTIVE: To evaluate the efficacy and safety of Kuhuang injection vs. Potassium magnesium aspartate in the treatment of viral hepatitis. METHODS: Retrieved from Cochrane Library, PubMed, EMBase, CNKI, VIP, CBM, randomized controlled trails (RCT) included on Kuhuang injection vs. Potassium magnesium aspartate in the treatment of viral hepatitis were evaluated and analyzed by the Rev Man 5.0 software. RESULTS: 8 studies involving 1 242 patients were included. The results of Meta-analysis demonstrated that Kuhuang injection was superior to Potassium magnesium aspartate in total effective rate, there was statistical significance [RR=1.34, 95%CI (1.22,1.46), P<0.000 01]. There was no statistically difference in incidence of ADR [RR=3.33,95%CI (0.16,69.75), Jp=0.44]. CONCLUSIONS: Kuhuang injection is better than Potassium magnesium aspartate in the treatment of viral hepatitis. However, due to the limited quantity and quality of the included studies, high-quality large-scale RCT are required.